In vivo, STING-deficient ID8 ovarian cancer mice model, AZD1775 (5 days on, 2 days off) combined with anti–PD-L1 antibody significantly enhanced anti-tumor efficacy (Guo et al., 2022). This evidence concerns the gene STING1 and neoplasm.